BI-3406, a selective KRAS-SOS1 interaction inhibitor, significantly ameliorates MEK inhibitor resistance in KRASG12C-mutant CRC cell lines and PDX models 138. This evidence concerns the gene MAP2K7 and colorectal carcinoma.